

Iran (Islamic Republic of)

COUNTRY GENERAL INFORMATION

Total population:	82 913 893
Gender F/M (%):	49.5 / 50.5
Population, age group <15 / ≥ 15 years (%):	25 / 75
Life expectancy at birth (F/M, years):	79 / 76
GDP (PPP int \$):	12 937
Income status:	Upper middle income
Number of 2 nd sub-national administrative level divisions, name:	348, County(Shahrestan)



EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	67	1169	6992	N/A
Number of relapses: ¹	No data	No data	No data	N/A
Total number of cases:	67	1169	6992	N/A
Imported cases (#, %):	No data	No data	No data	N/A
Gender distribution (% F):	No data	No data	No data	N/A
Age group distribution (% , <5 / 5-14 / >14):	No data	No data	No data	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.16	2.57	4.04	N/A
Number of endemic 2 nd sub-national administrative level divisions:	12	3	70	N/A
Population at risk (% , # at risk / total population): ²	5% 4 191 834/ 82 913 893	5% 4 545 324/ 82 913 893	21% 17 304 051/ 82 913 893	N/A
Was there any outbreak?	No data	No data	No data	N/A
Number of new foci: ³	No data	No data	No data	N/A



Monthly distribution of new cases (January-December)^A

2019	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	14	4	5	3	9	6	8	4	4	3	2	5
ACL	130	135	87	103	143	101	95	61	95	64	74	81
ZCL	1246	689	498	259	300	154	189	267	480	717	1093	1092

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



Number of new cases and incidence rate/10 000 at the national level from 2004 to 2019




^AFor cases with available subnational monthly data

¹Relapse in this country is defined for VL as: "Cure at the end of treatment and recurrence of clinical signs" and for CL as: "recurrence of cutaneous lesion after healing"

²Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

³Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL, ACL and ZCL cases at County level per 10 000 population (2019)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map production: WHO/UCN/NTD

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	2007
Type of surveillance (CL / VL):	Integrated / Integrated
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin
Year latest national guidelines (CL / VL):	2007 / 2014
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities (CL / VL):	170 / 460

DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	N/A
Number of people screened passively for:	No data	No data	No data	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	No data	No data	No data	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	No data	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	No data	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): No data / No data
- ▶ Antileishmanial medicines included in the National Medicine List: -

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	No data	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	No data	No data	No data
Failure rate (% , # cases with treatment failure / new cases): ⁴	No data	No data	No data
Case fatality rate (% , # cases who died / new cases):	No data	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴Failure in this country is defined for VL as: "Case with no cure at the end of treatment" and for CL as: "Absence of healing at the end of treatment"